c-Met receptor is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-02-13. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Identity checks for dihexa usually rely on mass spectrometry and chromatographic purity analysis. A lyophilized powder is the common supplied form, and it may appear as a white to off-white solid. Aqueous solubility is limited, so laboratory work often uses an organic solvent such as dimethyl sulfoxide to prepare stock solutions. Because the peptide is not a standard pharmaceutical product, exact specifications can vary between suppliers. Certificates of analysis may accompany a batch, but they are not equivalent to regulatory approval.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Identity and purity are usually assessed with reverse-phase high-performance liquid chromatography and mass spectrometry. These methods can separate related impurities and confirm molecular mass, but they do not by themselves establish biological activity. Certificate of analysis documents may report purity as a percentage by area, yet the exact meaning can vary between laboratories. Independent testing can check for residual solvents, counterions, or microbial contamination when relevant. For research use, matching analytical records to a specific lot helps trace experimental variability.
Dihexa occupies an uncertain regulatory space in many countries. It is not generally listed as an approved therapeutic, and some jurisdictions may treat it as a research chemical, a compounded substance, or an unapproved new drug depending on claims and distribution. Importation can be restricted, and suppliers may require documentation that the material is for laboratory research only. Quality and labeling vary, so buyers should request analytical data, verify lot numbers, and understand local rules. These factors make sourcing and compliance part of the practical context around dihexa.
Lyophilized dihexa is typically stored as a dry powder at or below minus twenty degrees Celsius. Cooler temperatures slow degradation, and desiccant protection limits moisture uptake. Repeated temperature cycling can accelerate breakdown, so aliquoting before storage is common in laboratory practice. Solutions are generally less stable than dry powder and are often kept cold, protected from light, and used within a defined period. Specific stability data for dihexa are limited, and handling recommendations often follow general peptide guidelines rather than compound-specific studies.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Dissolution depends on the peptide’s salt form, purity, and the chosen solvent. Dimethyl sulfoxide is commonly used to prepare concentrated stock solutions, while aqueous buffers may show limited solubility. Sonication or gentle warming can sometimes aid dissolution, but excessive heat may promote degradation. Once in solution, the material is generally kept cold and protected from light. Researchers should verify solubility for each lot rather than assuming uniform behavior across suppliers.
=== Chemotaxis === Neutrophils undergo a process called chemotaxis via amoeboid movement, which allows them to migrate toward sites of infection or inflammation. Cell surface receptors allow neutrophils to detect chemical gradients of molecules such as interleukin-8 (IL-8), interferon gamma (IFN-γ), C3a, C5a, and leukotriene B4, which these cells use to direct the path of their migration. Neutrophils have a variety of specific receptors, including ones for the complement system, cytokines like interleukins and IFN-γ, chemokines, lectins, and other proteins. They also express receptors to detect and adhere to endothelium and Fc receptors for opsonin. In leukocytes responding to a chemoattractant, the cellular polarity is regulated by activities of small Ras or Rho guanosine triphosphatases (Ras or Rho GTPases) and the phosphoinositide 3-kinases (PI3Ks). In neutrophils, lipid products of PI3Ks regulate activation of Rac1, hematopoietic Rac2, and RhoG GTPases of the Rho family and are required for cell motility. Ras-GTPases and Rac-GTPases regulate cytoskeletal dynamics and facilitate neutrophils adhesion, migration, and spreading. They accumulate asymmetrically to the plasma membrane at the leading edge of polarized cells. Spatially regulating Rho GTPases and organizing the leading edge of the cell, PI3Ks and their lipid products could play pivotal roles in establishing leukocyte polarity, as compass molecules that tell the cell where to crawl.
== Function == Maintains the intraocular pressure and inflates the globe of the eye. It is this hydrostatic pressure that keeps the eyeball in a roughly spherical shape and keeps the walls of the eyeball taut. Provides nutrition (e.g. amino acids and glucose) for the avascular ocular tissues; posterior cornea, trabecular meshwork, lens, and anterior vitreous. May serve to transport ascorbate in the anterior segment to act as an antioxidant agent. Presence of immunoglobulins indicates a role in immune response to defend against pathogens. Provides inflation for expansion of the cornea and thus increased protection against dust, wind, pollen grains, and some pathogens. Contributes refraction, with a refractive index of 1.3335 Prevents eye dryness.
== Relationship with astrobiology == Endolithic microorganisms have been considered a model for the search for life on other planets by inquiring about what sort of microorganisms on Earth inhabit specific minerals, which helps to propose those lithologies as life detection targets on an extra-terrestrial surface such as Mars. Several studies have been carried out in extreme places that serve as analogs for Mars's surface and subsurface, and many studies in geomicrobiology on Earth's hot and cold deserts have been developed. In these extreme environments, microorganisms find protection against thermal buffering, UV radiation, and desiccation while living inside pores and fissures of minerals and rocks. Life in these endolithic habitats might face similar stress due to the scarcity of water and high UV radiation that rule on modern Mars. An excellent example of these adaptations is the non-hygroscopic but microporous translucent gypsum crusts, which are found as potential substrates that can mitigate exposure to UV radiation and desiccation and allow microbial colonization in hyper-arid deserts. In the same way, the ability to grow under high water stress and oligotrophic conditions confer to endolithic microorganisms to survive in conditions similar to those found on Mars. There is evidence of the past existence of water on the red planet; perhaps, these microorganisms could develop adaptations found in current deserts on the Earth.
Leaning heavily into European free improvisation and avant-garde classical structures, the line-up eventually stripped down to a core trio of Fripp, Bruford, and Wetton, producing the highly acclaimed studio albums Larks' Tongues in Aspic (1973), Starless and Bible Black (1974), and Red (1974), before Fripp temporarily disbanded the group. King Crimson returned from a seven-year hiatus in 1981 with a revamped, transatlantic line-up featuring Fripp, Bruford, and American musicians Adrian Belew and Tony Levin. Incorporating elements of New York minimalism, gamelan, and contemporary new wave, this iteration recorded a distinct trilogy of studio albums: Discipline (1981), Beat (1982), and Three of a Perfect Pair (1984). After another decade-long dormancy, the band reconstituted in 1994 as a "Double Trio" sextet, adding Pat Mastelotto and Trey Gunn to release Thrak (1995). During the late 1990s, the band members also operated in smaller, improvised sub-groups known as "ProjeKcts". The main group continued into the early 2000s as a quartet, releasing The ConstruKction of Light (2000) and The Power to Believe (2003), which showcased a heavier, industrial-influenced sound. Following a brief 40th-anniversary tour in 2008 that introduced drummer Gavin Harrison, Fripp placed the group on hold until 2013. King Crimson then re-emerged as a highly structured touring septet (and later octet) featuring an unusual three-drummer frontline and lead vocalist Jakko Jakszyk.
In May 1878 Eddy brought a case against Daniel Spofford, in Salem, Massachusetts, for practicing mesmerism. It came to be known as the second Salem witchcraft trial. The case was filed in the name of one of Spofford's patients, Lucretia Brown, who said that he had bewitched her, though Eddy appeared in court on Brown's behalf. In preparation for the hearing, Eddy organized a 24-hour watch at 8 Broad Street, during which she asked 12 students to think about Spofford for two hours each and block malicious mesmerism from him. She arrived at the court with 20 supporters, including Amos Bronson Alcott (a "cloud of witnesses," according to the Boston Globe), but Judge Horace Gray dismissed the case. The attempt to have Spofford tried was not the end of the dispute. In October 1878 Eddy's husband and another student, Edward Arens, were charged with conspiring to murder Spofford. A barman said they had offered him $500 to do it; after a complex series of claims and counter-claims, the charges were dropped when a witness retracted his statement. Eddy attributed the allegation to a plot by former students to undermine sales of the second edition of Science and Health, just published. Her lawyer had to apply for an attachment order against her house to collect his fee.
Sources: en.wikipedia.org
It represents a false pocket, where the apparent deepening of the sulcus occurs due to coronal displacement of the gingival margin rather than apical migration of the JE. Pseudopockets develop primarily from inflammatory gingival edema or hyperplasia, most often secondary to plaque accumulation. Inflammation causes vascular congestion and collagen breakdown within the gingival connective tissue, resulting in swollen, soft, and puffy gingiva that bulges coronally. In pseudopockets, the JE remains at its normal position at the CEJ, and the connective tissue attachment remains intact. There is no alveolar bone loss, and the increased probing depth is solely due to gingival swelling. Clinically, pseudopockets are considered an early and reversible stage of periodontal disease, typically associated with gingivitis. However, if plaque accumulation persists, pseudopockets may progress to true periodontal pockets with CAL.
== External links == Biggest Collection of Medical Abbreviations Glossary of Medical Terms - Tufts University Medical Abbreviations EN English Medical Abbreviations for Android JD.MD, Inc. online Medical & Dental Abbreviations Glossary Acronyms for Medical & Dental professional organizations Medical Abbreviations for iPhone Medical abbreviations on mediLexicon Medical acronyms and abbreviations on allacronyms.com Over 20,000 medical abbreviations sorted into specialist categories Medical abbreviations in various categories such as Physiology, Oncology, Laboratory and more
A centenarian is a person who has reached the age of 100. Because life expectancies at birth worldwide are well below 100, the term is invariably associated with longevity. The United Nations estimated that there were 316,600 living centenarians worldwide in 2012, and 573,000 in 2020, almost quadruple the 2000 estimate of 151,000. As world population and life expectancy continue to increase, the number of centenarians is expected to increase substantially in the 21st century. According to the Office of National Statistics in the United Kingdom, one-third of babies born in the country in 2013 are expected to live to 100. According to a 1998 United Nations demographic survey, Japan is expected to have 272,000 centenarians by 2050; other sources suggest that the number could be closer to 1 million. The incidence of centenarians in Japan was one per 3,522 people in 2008. In Japan (as in most countries), the population of centenarians is highly skewed towards women. Japan in fiscal year 2016 had 57,525 female centenarians, while there were 8,167 males, a ratio of 7:1. The increase of centenarians was even more skewed, at 11.6:1.
The kidney is a vital organ with a variety of responsibilities. It plays an important role in maintaining the water, electrolyte and acid-base balance. It excretes toxic metabolic degradation products such as urea. It also recovers valuable substances such as glucose, amino acids, peptides and minerals initially filtered out of the blood during ultrafiltration in the renal corpuscles. In addition, endogenous and exogenous substances are metabolized and broken down in the kidneys—the kidney is therefore a central metabolic organ alongside the liver. Finally, some hormone-active substances are secreted by the kidney, such as renin, erythropoietin and calcitriol (active form of vitamin D3). As a result, the organ plays an important role in the regulation of blood pressure, new blood formation and the balance of calcium and phosphorus, and is thus crucial to bone metabolism, as well. As carnivores, cats are particularly dependent on the intake of animal proteins because glucose formation from amino acids is their most important energy source. The enzymes of amino acid degradation are adapted to the high protein intake and their activity is largely independent of the protein supply in the diet, so that cats break down endogenous proteins (especially from the muscles) when there is a lack of protein intake (catabolic metabolic state). Meat and offal also contain vital nutrients for the cat, such as Vitamin A, Taurin or arachidonic acid. Compared to a normal human diet, cats consume around six times as much phosphate in their diet with standard cat food.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.